12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Biosimilar rituximab: Phase III halted

Samsung Group (Seoul, South Korea) has "temporarily halted" a clinical trial of its biosimilar version of autoimmune and cancer drug MabThera rituximab in 2 countries, according to the EU clinical trials register. The trial's listing states that it was halted in the Czech Republic and Spain, but is continuing in the U.K., Hungary and Poland. Last year, Samsung announced a...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >